<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82274">
  <stage>Registered</stage>
  <submitdate>10/09/2007</submitdate>
  <approvaldate>19/09/2007</approvaldate>
  <actrnumber>ACTRN12607000470493</actrnumber>
  <trial_identification>
    <studytitle>Topical vapocoolant spray in reducing the pain of intravenous cannulation in the emergency department: a randomised, single-blinded, placebo-controlled trial</studytitle>
    <scientifictitle>A randomised controlled clinical trial to compare the efficacy of pressurised vapocoolant and water sprays in decreasing the pain of intravenous cannulation in emergency department patients.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Pain of intravenous cannulation</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Two second spray of pressurised vapocoolant "COLD Spray" (butane, propane, pentane blend), from 12 cm, to the IV cannulation site. The alkane blend may vary with the batch and specific proportions of the three alkanes are not available</interventions>
    <comparator>Two second spray of pressurised Evian water spray, from 12 cm, to the IV cannulation site</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain score of intravenous cannulation (0-100) on a visual analogue scale</outcome>
      <timepoint>One minute after cannulation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Thrombophlebitis, blistering, frostbite, redness, and swelling at the cannulation site</outcome>
      <timepoint>Five days after cannulation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Emergency department patients, aged 18 years or more, requiring intravenous cannulation.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>-2147483648</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Refusal to provide consent; Inability to provide informed consent (Non-English speaking, altered mental state, significant illness); Moderate to severe discomfort or pain; Diseases of the skin associated with cold intolerance (eg: Raynauds phenomenon); Known allergy to spray contents; Peripheral neuropathy; Parenteral analgesia in the previous 4 hours</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A note containing each individual patient's allocation will be inside a sealed envelope inside each study pack</concealment>
    <sequence>computer generated random numbers</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Only the researcher administering the intervention/control spray will know the allocation. He/she will only apply the spray but will not allocate the treatment, insert the cannula, measure the pain score or analyse the data.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/10/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3084</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Health</primarysponsorname>
    <primarysponsoraddress>Studley Road
Heidelberg
Victoria</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Austin Health</fundingname>
      <fundingaddress>Studley Road
Heidelberg
Victoria</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Vapocollant spray is used overseas to decrease the pain of intravenous cannulation. However, no randomised controlled trial has been reported to provide evidence for this.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress>Studley Road
Heidelberg
Victoria</ethicaddress>
      <ethicapprovaldate>12/11/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>17/09/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof David Taylor</name>
      <address>Emergency Department
Austin Health
Studley Rd
Heidelberg
Victoria</address>
      <phone>03 9496 4883</phone>
      <fax>03 9496 3380</fax>
      <email>David.Taylor@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof David Taylor</name>
      <address>Emergency Department
Austin Health
Studley Rd
Heidelberg
Victoria</address>
      <phone>03 9496 4883</phone>
      <fax>03 9496 3380</fax>
      <email>David.Taylor@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof David Taylor</name>
      <address>Emergency Department
Austin Health
Studley Rd
Heidelberg
Victoria</address>
      <phone>03 9496 4883</phone>
      <fax>03 9496 3380</fax>
      <email>David.Taylor@austin.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>